Biomarkers in amyotrophic lateral sclerosis: Facts and future horizons

Molecular Diagnosis and Therapy

Volumn 13, Issue 2, 2009, Pages 115-125

  Pradat, Pierre Franois ^a,b   Dib, Michel ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COPPER ZINC SUPEROXIDE DISMUTASE; TAR DNA BINDING PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; BLOOD LEVEL; CEREBROSPINAL FLUID; DIFFUSION TENSOR IMAGING; DISEASE COURSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; METABOLOMICS; MUSCLE LEVEL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEOMICS; RADIOLOGICAL PARAMETERS; REVIEW; TRANSCRIPTOMICS;

AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MUSCLE, SKELETAL; POSITRON-EMISSION TOMOGRAPHY;

EID: 67650480216     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/bf03256320     Document Type: Review

References (108)

1. Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293-9
2. Pradat PF, Bruneteau G. Quels sont les critères cliniques de la sclérose latérale amyotrophique en fonction des formes cliniques? Rev Neurol (Paris) 2006; 162 (2): 4S29-33
3. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344: 1688-700
4. Swash M. Clinical features and diagnosis of amyotrophic lateral sclerosis. In: Brown Jr RH, Meininger V, Swash M, editors. Amyotrophic lateral sclerosis. London: Martin Dunitz, 2000: 3-30
5. Forman MS, Trojanowski JQ, Lee VM. TDP-43: a novel neurodegenerative proteinopathy. Curr Opin Neurobiol 2007; 17: 548-55
6. Pradat PF, Bruneteau G. Quels sont les signes cliniques, classiques et inhabituels, devant faire évoquer une sclérose latérale amyotrophique? Rev Neurol (Paris) 2006; 162 (2): 4S17-24
7. de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 2008; 119: 497-503
8. Mackenzie IR, Bigio EH, Ince PG, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007; 61: 427-34
9. Shankar SK, Yanagihara R, Garruto RM, et al. Immunocytochemical characterization of neurofibrillary tangles in amyotrophic lateral sclerosis and parkinsonism-dementia of Guam. Ann Neurol 1989; 25: 146-51
10. Traynor BJ, Codd MB, Corr B, et al. Amyotrophic lateral sclerosis mimic syndromes: a population-based study. Arch Neurol 2000; 57: 109-13
11. Beghi E, Millul A, Micheli A, et al. Incidence of ALS in Lombardy, Italy. Neurology 2007; 68: 141-5
12. Beghi E, Mennini T, Bendotti C, et al. The heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failure. Curr Med Chem 2007; 14: 3185-200
13. Logroscino G, Traynor BJ, Hardiman O, et al. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry 2008; 79: 6-11
14. Iwasaki Y, Ikeda K, Ichikawa Y, et al. The diagnostic interval in amyotrophic lateral sclerosis. Clin Neurol Neurosurg 2002; 104: 87-9
15. Zoccolella S, Beghi E, Palagano G, et al. Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: a population-based study. J Neurol Sci 2006; 250: 45-9
16. Chio A, Mora G, Leone M, et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 2002; 59: 99-103
17. Traynor BJ, Codd MB, Corr B, et al. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: a population-based study. Arch Neurol 2000; 57: 1171-6
18. Riviere M, Meininger V, Zeisser P, et al. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 1998; 55: 526-8
19. Paillisse C, Lacomblez L, Dib M, et al. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. Amyotroph Lateral Scler Other Motor Neuron Disord 2005; 6: 37-44
20. Kunst CB. Complex genetics of amyotrophic lateral sclerosis. Am J Hum Genet 2004; 75: 933-47
21. Camu W. Sclerose latérale amyotrophique: des formes monogéniques aux formes multigéniques. Neurologies 2003; 6: 517-20
22. Kabashi E, Valdmanis PN, Dion P, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 2008; 40: 572-4
23. Kwiatkowski Jr TJ, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009; 323: 1205-8
24. Vance C, Rogelj B, Hortobagyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009; 323: 1208-11
25. Schymick JC, TalbotK, Traynor BJ. Geneticsofsporadic amyotrophic lateral sclerosis. Hum Mol Genet 2007; 16 (2): R233-42
26. Simpson EP, Henry YK, Henkel JS, et al. Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden. Neurology 2004; 62: 1758-65
27. Ilzecka J, Stelmasiak Z, Dobosz B. Transforming growth factor-beta 1 (tgf-beta 1) in patients with amyotrophic lateral sclerosis. Cytokine 2002; 20: 239-43
28. Spreux-Varoquaux O, Bensimon G, Lacomblez L, et al. Glutamate levels in cerebrospinal fluidin amyotrophic lateralsclerosis:a reappraisal using anew HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci 2002; 193: 73-8
29. Baron P, Bussini S, Cardin V, et al. Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis. Muscle Nerve 2005; 32: 541-4
30. Kuzma M, Jamrozik Z, Baranczyk-Kuzma A. Activity and expression of glutathione S-transferase pi in patients with amyotrophic lateral sclerosis. Clin Chim Acta 2006; 364: 217-21
31. Ihara Y, Nobukuni K, Takata H, et al. Oxidative stress and metal content in blood and cerebrospinal fluid of amyotrophic lateral sclerosis patients with and without a Cu, Zn-superoxide dismutase mutation. Neurol Res 2005; 27: 105-8
32. Sohmiya M, Tanaka M, Suzuki Y, et al. An increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patients. J Neurol Sci 2005; 228: 49-53
33. Ferri A, Nencini M, Battistini S, et al. Activity of protein phosphatase calcineurin isdecreasedinsporadic and familial amyotrophic lateral sclerosis patients. J Neurochem 2004; 90: 1237-42
34. Ilzecka J, Stelmasiak Z. Serum bilirubin concentration in patients with amyotrophic lateral sclerosis. Clin Neurol Neurosurg 2003; 105: 237-40
35. Nygren I, Larsson A, Johansson A, et al. VEGF is increased in serum but not in spinal cord from patients with amyotrophic lateral sclerosis. Neuroreport 2002; 13: 2199-201
36. Houi K, Kobayashi T, Kato S, et al. Increased plasma TGF-beta1 in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2002; 106: 299-301
37. Ilzecka J. Decreased serum endoglin level in patients with amyotrophic lateral sclerosis: a preliminary report. Scand J Clin Lab Invest 2008; 68: 348-51
38. Ilzecka J. Increased serum CNTF level in patients with amyotrophic lateral sclerosis. Eur Cytokine Netw 2003; 14: 192-4
39. Ilzecka J. Decreased serum-soluble TRAIL levels in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2008; 117: 343-6
40. Ilzecka J. Prostaglandin E2 is increased in amyotrophic lateral sclerosis patients. Acta Neurol Scand 2003; 108: 125-9
41. Demestre M, Parkin-Smith G, Petzold A, et al. The pro and the active form of matrix metalloproteinase-9 is increased in serum of patients with amyotrophic lateral sclerosis. J Neuroimmunol 2005; 159: 146-54
42. Dupuis L, Corcia P, Fergani A, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 2008; 70: 1004-9
43. Steele AJ, al Chalabi A, Ferrante K, et al. Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives. Neurology 2005; 64: 454-8
44. Lacomblez L,Doppler V, Beucler I, etal. APOE: apotential marker ofdisease progression in ALS. Neurology 2002; 58: 1112-4
45. Boll MC, Alcaraz-Zubeldia M, Montes S, et al. Raised nitrate concentration and low SOD activity in the CSF of sporadic ALS patients. Neurochem Res 2003; 28: 699-703
46. Kaufmann E, Boehm BO, Sussmuth SD, et al. The advanced glycation endproduct N epsilon-(carboxymethyl)lysine level is elevated in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Neurosci Lett 2004; 371: 226-9
47. Kuncl RW, Bilak MM, Bilak SR, et al. Pigment epithelium-derived factor is elevated in CSF of patients with amyotrophic lateral sclerosis. J Neurochem 2002; 81: 178-84
48. Devos D, Moreau C, Lassalle P, et al. Low levels of the vascular endothelial growth factor in CSF from early ALS patients. Neurology 2004; 62: 2127-9
49. Ilzecka J. Cerebrospinal fluid vascular endothelial growth factor in patients with amyotrophic lateral sclerosis. Clin Neurol Neurosurg 2004; 106: 289-93
50. Ilzecka J. Cerebrospinal fluid Flt3 ligand level in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2006; 114: 205-9
51. Tanaka M, KikuchiH, IshizuT,et al. Intrathecal upregulation ofgranulocyte colony stimulating factor and its neuroprotective actions on motor neurons in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2006; 65: 816-25
52. Ilecka J. Decreased cerebrospinal fluid cGMP levels in patients with amyotrophic lateral sclerosis. J Neural Transm 2004; 111: 167-72
53. Fischer LR, Culver DG, Tennant P, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol 2004; 185: 232-40
54. Jokic N, Gonzalez de Aguilar JL, Dimou L, et al. The neurite outgrowth inhibitor Nogo-A promotes denervation in an amyotrophic lateral sclerosis model. EMBO Rep 2006; 7: 1162-7
55. Rouaux C, Panteleeva I, Rene F, et al. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J Neurosci 2007; 27: 5535-45
56. Dupuis L, Gonzalez de Aguilar JL, Di Scala F, et al. Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis. Neurobiol Dis 2002; 10: 358-65
57. Pradat PF, Bruneteau G, Gonzalez de Aguilar JL, et al. Muscle Nogo-A expression is a prognostic marker in lower motor neuron syndromes. Ann Neurol 2007; 62: 15-20
58. Jokic N, Gonzalez de Aguilar JL, Pradat PF, et al. Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity. Ann Neurol 2005; 57: 553-6
59. Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999; 169: 13-21
60. Wojcik S, Engel WK, Askanas V. Increased expression of Noga-A in ALS muscle biopsies is not unique for this disease. Acta Myol 2006; 25: 116-8
61. Wojcik S,Engel WK, YanR,et al. NOGO is increased and binds to BACE1 in sporadic inclusion-body myositis and in AbetaPP-overexpressing cultured human muscle fibers. Acta Neuropathol 2007; 114: 517-26
62. Pradat PF, Gonzalez de Aguilar JL, Bruneteau G, et al. Specificity for amyotrophic lateral sclerosis of Nogo-A muscle expression [author reply]. Ann Neurol 2008; 62: 676-7
63. Pasinetti GM, Ungar LH, Lange DJ, et al. Identification of potential CSF biomarkers in ALS. Neurology 2006; 66: 1218-22
64. Gonzalez de Aguilar JL, Niederhauser-Wiederkehr C, Halter B, et al. Gene profiling of skeletal muscle in an amyotrophic lateral sclerosis mouse model. Physiol Genomics 2008; 32: 207-18
65. Pradat PF, Bruneteau G. Quels sont les diagnostics differentiels et les formes frontieres de SLA? Rev Neurol (Paris) 2006; 162 (2): 4S81-90
66. Oba H, Araki T, Ohtomo K, et al. Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. Radiology 1993; 189: 843-6
67. Cheung G, Gawel MJ, Cooper PW, et al. Amyotrophic lateral sclerosis: correlation of clinical and MR imaging findings. Radiology 1995; 194: 263-70
68. Comi G, Rovaris M, Leocani L. Review neuroimaging in amyotrophic lateral sclerosis. Eur J Neurol 1999; 6: 629-37
69. Ellis CM, Simmons A, Jones DK, et al. Diffusion tensor MRI assesses corticospinal tract damage in ALS. Neurology 1999; 53: 1051-8
70. Goodin DS, Rowley HA, Olney RK. Magnetic resonance imaging in amyotrophic lateral sclerosis. Ann Neurol 1988; 23: 418-20
71. Hecht MJ, Fellner F, Fellner C, et al. MRI-FLAIR images of the head show corticospinal tract alterations in ALS patients more frequently than T2-, T1- and proton-density-weighted images. J Neurol Sci 2001; 186: 37-44
72. Hofmann E, Ochs G, Pelzl A, et al. The corticospinal tract in amyotrophic lateral sclerosis: an MRI study. Neuroradiology 1998; 40: 71-5
73. Kato Y, Matsumura K, Kinosada Y, et al. Detection of pyramidal tract lesions in amyotrophic lateral sclerosis with magnetization-transfer measurements. AJNR Am J Neuroradiol 1997; 18: 1541-7
74. Mirowitz S, Sartor K, Gado M, et al. Focal signal-intensity variations in the posterior internal capsule: normal MR findings and distinction from pathologic findings. Radiology 1989; 172: 535-9
75. Tanabe JL, Vermathen M, Miller R, et al. Reduced MTR in the corticospinal tract and normal T2 in amyotrophic lateral sclerosis. Magn Reson Imaging 1998; 16: 1163-9
76. Thorpe JW, Moseley IF, Hawkes CH, et al. Brain and spinal cord MRI in motor neuron disease. J Neurol Neurosurg Psychiatry 1996; 61: 314-7
77. Waragai M. MRI and clinical features in amyotrophic lateral sclerosis. Neuroradiology 1997; 39: 847-51
78. Graham JM, Papadakis N, Evans J, et al. Diffusion tensor imaging for the assessment of upper motor neuron integrity in ALS. Neurology 2004; 63: 2111-9
79. Winhammar JM, Rowe DB, Henderson RD, et al. Assessment of disease progression in motor neuron disease. Lancet Neurol 2005; 4: 229-38
80. Valsasina P, Agosta F, Benedetti B, et al. Diffusion anisotropy of the cervical cord is strictly associated with disability in ALS. J Neurol Neurosurg Psychiatry 2006; 78: 480-4
81. Pohl C, Block W, Karitzky J, et al. Proton magnetic resonance spectroscopy of the motor cortex in 70 patients with amyotrophic lateral sclerosis. Arch Neurol 2001; 58: 729-35
82. Sarchielli P,Pelliccioli GP, Tarducci R, etal. Magnetic resonance imaging and 1H-magnetic resonance spectroscopy in amyotrophic lateral sclerosis. Neuroradiology 2001; 43: 189-97
83. Suhy J, Miller RG, Rule R, et al. Early detection and longitudinal changes in amyotrophic lateral sclerosis by (1)H MRSI. Neurology 2002; 58: 773-9
84. Gredal O, Rosenbaum S, Topp S, et al. Quantification of brain metabolites in amyotrophic lateral sclerosis by localized proton magnetic resonance spectroscopy. Neurology 1997; 48: 878-81
85. Pioro EP, Antel JP, Cashman NR, et al. Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. Neurology 1994; 44: 1933-8
86. Kalra S, Hanstock CC, Martin WR, et al. Detection of cerebral degeneration in amyotrophic lateral sclerosis using high-field magnetic resonance spectroscopy. Arch Neurol 2006; 63: 1144-8
87. Sach M, Winkler G, Glauche V, et al. Diffusion tensor MRI of early upper motor neuron involvement in amyotrophic lateral sclerosis. Brain 2004; 127: 340-50
88. Sage CA, Peeters RR, Gorner A, et al. Quantitative diffusion tensor imaging in amyotrophic lateral sclerosis. Neuroimage 2007; 34: 486-99
89. Thivard L, Pradat PF, Lehericy S, et al. Diffusion tensor imaging and voxel based morphometry study in amyotrophic lateral sclerosis: relationships with motor disability. J Neurol Neurosurg Psychiatry 2007; 78: 889-92
90. Mitsumoto H, Ulug AM, Pullman SL, et al. Quantitative objective markers for upper and lower motor neuron dysfunction in ALS. Neurology 2007; 68: 1402-10
91. Wong JC, Concha L, Beaulieu C, et al. Spatial profiling of the corticospinal tract in amyotrophic lateral sclerosis using diffusion tensor imaging. J Neuroimaging 2007; 17: 234-40
92. Schimrigk SK, Bellenberg B, Schluter M, et al. Diffusion tensor imagingbased fractional anisotropy quantification in the corticospinal tract of patients with amyotrophic lateral sclerosis using a probabilistic mixture model. AJNR Am J Neuroradiol 2007; 28: 724-30
93. Blain CRV, Williams VC, Johnston C, et al. A longitudinal study of diffusion tensor MRI in ALS. Amyotroph Lateral Scler 2007; 8: 348-55
94. Abe O, Yamada H, Masutani Y, et al. Amyotrophic lateral sclerosis: diffusion tensor tractography and voxel-based analysis. NMR Biomed 2004; 17: 411-6
95. Ciccarelli O, Behrens TE, Altmann DR, et al. Probabilistic diffusion tractography: a potential tool to assess the rate of disease progression in amyotrophic lateral sclerosis. Brain 2006; 129: 1859-71
96. Grosskreutz J, Kaufmann J, Fradrich J, et al. Widespread sensorimotor and frontal cortical atrophy in amyotrophic lateral sclerosis. BMC Neurol 2006; 6: 17
97. Waragai M, Takaya Y, Hayashi M. Serial MRI and SPECT in amyotrophic lateral sclerosis: a case report. J Neurol Sci 1997; 148: 117-20
98. 99mTc]-d,l-HMPAO SPECT study. J Neurol Sci 1992; 107: 19-28
99. Abe K, Yorifuji S, Nishikawa Y. Reduced isotope uptake restricted to the motor area in patients with amyotrophic lateral sclerosis. Neuroradiology 1993; 35: 410-1
100. Kalra S, Arnold D. Neuroimaging in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4: 243-8
101. Habert MO, Lacomblez L, Maksud P, et al. Brain perfusion imaging in amyotrophic lateral sclerosis: extent of cortical changes according to the severity and topography of motor impairment. Amyotroph Lateral Scler 2007; 8: 9-15
102. Hoffman JM, Mazziotta JC, Hawk TC, et al. Cerebral glucose utilization in motor neuron disease. Arch Neurol 1992; 49: 849-54
103. Hatazawa J, Brooks RA, Dalakas MC, et al. Cortical motor-sensory hypometabolism in amyotrophic lateral sclerosis: a PET study. J Comput Assist Tomogr 1988; 12: 630-6
104. 11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS. Brain 2005; 128: 896-905
105. 11C](R)-PK11195 positron emission tomography study. Neurobiol Dis 2004; 15: 601-9
106. Kew JJ, Leigh PN, Playford ED, et al. Cortical function in amyotrophic lateral sclerosis: a positron emission tomography study. Brain 1993; 116 (Pt 3): 655-80
107. KonradC, Henningsen H,BremerJ,et al. Patternof cortical reorganization in amyotrophic lateral sclerosis: a functional magnetic resonance imaging study. Exp Brain Res 2002; 143: 51-6
108. Unrath A, Ludolph AC, Kassubek J. Brain metabolites in definite amyotrophic lateral sclerosis: a longitudinal proton magnetic resonance spectroscopy study. J Neurol 2007; 254: 1099-106